Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab
Study Identifier:
SHEPHERD
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: eculizumab
Date
Dec 2004 - N/A
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: eculizumab
Date
Dec 2004 - N/A
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
The primary objective is to evaluate the safety of eculizumab in patients with transfusion-dependent hemolytic PNH
Trial Locations
Location
Status
Location
Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Status
N/A
Location
Stanford University Medical Center, Division of Hematology
Stanford, California, United States, 94305
Status
N/A
Location
Hartford Hospital, Cancer Clinical Research Office
Hartford, Connecticut, United States, 06102
Status
N/A
Location
Cleveland Clinic Florida, Dept. of Clinical Research
Weston, Florida, United States, 33331
Status
N/A
Location
Indiana University Cancer Pavilion
Indianapolis, Indiana, United States, 46202
Status
N/A
Location
Johns Hopkins University Medical Center
Baltimore, Maryland, United States, 21205
Status
N/A